Pfizer's Growth Shift Beyond COVID-19 Products Accelerates — Company Talk

What happened

Pfizer's third-quarter revenue shows new launches and acquisitions driving growth, with operational sales of launched and acquired treatments up 32% year over year. Cancer drug Padcev rose 55% and blood thinner Eliquis gained 25%, offsetting a 63% drop in Paxlovid and a 29% decline in Comirnaty sales.

Confirmed

Global impact / market context

This matters because Pfizer is replacing shrinking COVID-19 product revenue with cancer and rare disease treatments bought through acquisitions. If those newer drugs keep growing, Pfizer can stabilize total sales and reduce dependence on volatile pandemic-era demand, which supports more predictable future earnings for investors.

Analyst inference

Large drugmakers are shifting away from pandemic products toward oncology and rare disease, where prices are higher and competition is often specialized. Pfizer's 7% rise in non-COVID operational revenue suggests the transition is progressing, but investors will judge whether acquisition-driven growth can fully offset declining vaccine and antiviral sales.

Analyst inference

What to watch

1. Watch whether Padcev keeps growing at its 55% pace, since cancer drugs are now central to replacing lost COVID-19 revenue and supporting Pfizer's overall sales base. Confirmed
2. Watch for Pfizer to pursue more oncology and rare disease acquisitions, a move the article highlights as central to replacing waning COVID-19 vaccine demand over coming quarters. Proposed
3. Watch whether non-COVID operational revenue keeps rising 7% or faster, because slower growth would make it harder to offset future declines in Paxlovid and Comirnaty sales. Analyst inference

Evidence

• Original source link unavailable